December 13, 2019

BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer

December 5, 2019

BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer

November 26, 2019

BioLineRx to Host Investor and Analyst Breakfast Meeting on December 5, 2019 in New York